These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24115652)

  • 41. Proteins of the extracellular matrix in vitreoretinal membranes.
    Scheiffarth OF; Kampik A; Günther H; von der Mark K
    Graefes Arch Clin Exp Ophthalmol; 1988; 226(4):357-61. PubMed ID: 3049258
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy.
    Costa Ede P; Rodrigues EB; Farah ME; Sebag J; Meyer CH
    Curr Pharm Biotechnol; 2011 Mar; 12(3):410-22. PubMed ID: 20939794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of the molecular biologic milieu of the vitreous in proliferative vitreoretinopathy.
    Wladis EJ; Falk NS; Iglesias BV; Beer PM; Gosselin EJ
    Retina; 2013 Apr; 33(4):807-11. PubMed ID: 23222459
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy.
    Simó-Servat O; Hernández C; Simó R
    Mediators Inflamm; 2012; 2012():872978. PubMed ID: 23028204
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Isotope-coded protein label based quantitative proteomic analysis reveals significant up-regulation of apolipoprotein A1 and ovotransferrin in the myopic chick vitreous.
    Yu FJ; Lam TC; Liu LQ; Chun RK; Cheung JK; Li KK; To CH
    Sci Rep; 2017 Oct; 7(1):12649. PubMed ID: 28978931
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic vitreoretinopathy.
    Hattenbach LO; Allers A; Gümbel HO; Scharrer I; Koch FH
    Retina; 1999; 19(5):383-9. PubMed ID: 10546932
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study.
    Kon CH; Occleston NL; Aylward GW; Khaw PT
    Invest Ophthalmol Vis Sci; 1999 Mar; 40(3):705-12. PubMed ID: 10067974
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elevated adrenomedullin in the vitreous of patients with proliferative vitreoretinopathy.
    Udono T; Takahashi K; Takano S; Shibahara S; Tamai M
    Am J Ophthalmol; 1999 Dec; 128(6):765-7. PubMed ID: 10612519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Localization of acidic fibroblast growth factor in proliferative vitreoretinopathy membranes.
    Malecaze F; Mathis A; Arné JL; Raulais D; Courtois Y; Hicks D
    Curr Eye Res; 1991 Aug; 10(8):719-29. PubMed ID: 1717200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantitative Proteomics Analysis of Vitreous Humor from Diabetic Retinopathy Patients.
    Loukovaara S; Nurkkala H; Tamene F; Gucciardo E; Liu X; Repo P; Lehti K; Varjosalo M
    J Proteome Res; 2015 Dec; 14(12):5131-43. PubMed ID: 26490944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitative proteomics analysis of vitreous body from type 2 diabetic patients with proliferative diabetic retinopathy.
    Li J; Lu Q; Lu P
    BMC Ophthalmol; 2018 Jun; 18(1):151. PubMed ID: 29940965
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dissection of human vitreous body elements for proteomic analysis.
    Skeie JM; Mahajan VB
    J Vis Exp; 2011 Jan; (47):. PubMed ID: 21304469
    [TBL] [Abstract][Full Text] [Related]  

  • 53. LC-MS/MS Analysis Elucidates a Daily Rhythm in Orexin A Concentration in the Rat Vitreous Body.
    Chrobok L; Bajkacz S; Klich JD; Lewandowski MH
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ocular penetration of ceftriaxone, ceftazidime, and vancomycin after subconjunctival injection in humans.
    Barza M; Doft B; Lynch E
    Arch Ophthalmol; 1993 Apr; 111(4):492-4. PubMed ID: 8470981
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravitreal Pharmacokinetic Study of the Antiangiogenic Glycoprotein Opticin.
    Del Amo EM; Griffiths JR; Klaska IP; Hoke J; White A; Aarons L; Cooper GJS; Bainbridge JWB; Bishop PN; Unwin RD
    Mol Pharm; 2020 Jul; 17(7):2390-2397. PubMed ID: 32437164
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Matrix metalloproteinases and their inhibitors in human vitreous.
    De La Paz MA; Itoh Y; Toth CA; Nagase H
    Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1256-60. PubMed ID: 9620087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The extracellular matrix of reparative tissue in the vitreous: fibronectin production in proliferative diabetic retinopathy membranes.
    Hiscott P; Waller HA; Grierson I; Butler MG; Scott DL
    Eye (Lond); 1993; 7 ( Pt 2)():288-92. PubMed ID: 7607348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regional distribution of phospholipids in porcine vitreous humor.
    Schnepf A; Yappert MC; Borchman D
    Exp Eye Res; 2017 Jul; 160():116-125. PubMed ID: 28552385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combining bioinformatics and MS-based proteomics: clinical implications.
    Acosta-Martin AE; Lane L
    Expert Rev Proteomics; 2014 Jun; 11(3):269-84. PubMed ID: 24720436
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Applying Proteomics to Investigate Extracellular Matrix in Health and Disease.
    Randles M; Lennon R
    Curr Top Membr; 2015; 76():171-96. PubMed ID: 26610914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.